Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00055861
Status:
COMPLETED
Last Update Posted:
2013-06-04
First Post:
2003-03-06
Brief Title:
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
PHASE 2 STUDY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH ADVANCED BREAST CANCER
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is to see if combining bevacizumab with docetaxel works in treating women who have locally advanced or metastatic breast cancer Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die Monoclonal antibodies such as bevacizumab can block cancer growth in different ways Some block the ability of cancer cells to grow and spread Others find cancer cells and help kill them or deliver cancer-killing substances to them Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells
Detailed Description:
PRIMARY OBJECTIVES
I Determine the response rate in women with locally advanced or metastatic breast cancer treated with bevacizumab and docetaxel
II Determine the side effects of this regimen in these patients III Correlate soluble activated endothelial cell markers and adhesion molecules quantitation of tumor andor endothelial cell apoptosis and quantitation of microvessel density with clinical outcome in patients treated with this regimen
OUTLINE This is a multicenter study Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1 2 and 3 Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression After completion of 6 courses of combined treatment patients with an ongoing response may receive bevacizumab alone in the absence of disease progression
PROJECTED ACCRUAL A total of 16-27 patients will be accrued for this study within 14-27 months
I Determine the response rate in women with locally advanced or metastatic breast cancer treated with bevacizumab and docetaxel
II Determine the side effects of this regimen in these patients III Correlate soluble activated endothelial cell markers and adhesion molecules quantitation of tumor andor endothelial cell apoptosis and quantitation of microvessel density with clinical outcome in patients treated with this regimen
OUTLINE This is a multicenter study Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1 2 and 3 Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression After completion of 6 courses of combined treatment patients with an ongoing response may receive bevacizumab alone in the absence of disease progression
PROJECTED ACCRUAL A total of 16-27 patients will be accrued for this study within 14-27 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000271359 | None | None | None |
| OSU 0218 | None | None | None |
| NCI-2715 | None | None | None |
| OSU-0218 | None | None | None |
| UCHSC-01239 | None | None | None |